Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 26, 2020

View Archived Issues

City of Hope begins phase I testing of investigational SARS-CoV-2 vaccine COH-04S1

Altimmune submits IND application with the FDA for phase I study of AdCOVID

Equillium decides not to start phase III study of itolizumab for COVID-19

Kinnate Biopharma patents Raf kinase inhibitors

Constellation Pharmaceuticals synthesizes TREX1 inhibitors

Aclaris Therapeutics identifies new JAK inhibitors

Incyte synthesizes CDK2/cyclin E inhibitors

Bluebird bio divulges non-natural T cells for cancer

InMed reports results from an initial phase I trial of INM-755 healthy subjects

FDA grants accelerated approval to Danyelza for neuroblastoma

Chinese approval for phase I/II study of ATG-016 for MDS

ICT presents a novel CoupledCAR technology against colorectal cancer

Health Canada approves Lynparza as treatment of BRCA or ATM gene-mutated mCRPC

MetrioPharm plans to conduct a phase II study of MP-1032 in patients with COVID-19

Karyopharm presents phase III data from SEAL study of Xpovio in liposarcoma

Targeting lung metastases is EASI way to induce systemic immunity

ADG-2: preclinical results of a neutralizing antibody for human SARS-CoV-2

FDA proposes conduct of additional exploratory analyses for omaveloxolone in Friedreich's ataxia

Senhwa files INDs in U.S. and Canada to study CX-5461 for solid tumors with BRCA2 or PALB2 mutations

Phase I data presented for rCSP-based malaria vaccine

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 5, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Study identifies CAND1 as therapeutic target in hepatoblastoma
BioWorld Science
Hepatoblastoma is the most common liver cancer during childhood, with limited therapeutic options in aggressive or relapsed cases. NEDDylation is a...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...